Request Deal Involvement

Gilead Sciences to acquire a 49.9% stake in Tizona Therapeutics for $300m.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

Squire Patton Boggs

legal advisors

Squire Patton Boggs

Ropes & Gray

legal advisors

Ropes & Gray

TD Cowen

financial advisors

TD Cowen

or

Principals

TIZONA THERAPEUTICS

target

TIZONA THERAPEUTICS

GILEAD SCIENCES

bidder

GILEAD SCIENCES

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Gilead Sciences to acquire a 49.9% stake in Tizona Therapeutics for $300m.